Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 43Lymphoma, Large B-Cell, Diffuse 35Burkitt Lymphoma 33Lymphoma 26Lymphoma, Follicular 16Rhabdomyosarcoma 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, B-Cell 12Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Leukemia 10Sarcoma, Ewing 9Leukemia, Biphenotypic, Acute 9Recurrence 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 8Lymphoma, T-Cell, Peripheral 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Hodgkin Disease 7Wilms Tumor 5Sarcoma 5Retinoblastoma 5Osteosarcoma 4Lymphoproliferative Disorders 4Lymphoma, T-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Ganglioneuroblastoma 4Down Syndrome 4

Interventions

Vincristine 1Radiotherapy 1Irinotecan 1Ifosfamide 1Filgrastim 1Etoposide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant mesenchymal tumor × Vincristine × 1 year × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡